VALLEY COTTAGE, N.Y., May 23, 2018 (GLOBE NEWSWIRE) -- Widespread acceptance of liquid biopsy technique in North America and steady adoption in developing regions is expected to drive global liquid biopsy market revenues. The global market is expected to reach US$ 407 Mn in 2016, up from US$ 351 Mn in 2015. North America will continue to remain the largest market for liquid biopsy, accounting for over 50% share of the global market.
The minimally-invasive nature and economical affordability of liquid biopsy tests will play a key role in bolstering demand globally. FDA approvals for non-invasive diagnostic tests for cancers is expected to have a positive influence on the growth of the market.
An increasing number of biotechnology and pharmaceutical companies are pushing the demand for liquid biopsy for anti-cancerous drug development. Moreover, oncologists are more inclined toward liquid biopsy for cancer detection. Government funding for R&D and clinical trials for diagnostics, treatment, and prevention are other key factors fuelling adoption of liquid biopsy. In contrast, higher cost of liquid biopsy compared to conventional diagnostic techniques, and low awareness regarding liquid biopsy tests can pose challenges to growth.
Request a Sample Report with Table of Contents and Figures : https://www.futuremarketinsights.com/reports/...ep-gb-1396
By bio marker type, circulating tumour cells (CTCs) segment is expected to form the most attractive market segment, contributing more than 60% of the revenue share to the market. On the basis of the sample type, the segment for blood sample will reflect the highest growth potential, with over 93% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth throughout 2016.
By disease indication, lung cancer segment is expected to dominate the market, in terms of revenues. By end user, cancer institutes are estimated to represent a revenue share of around 38% -- significantly higher compared to other end-use segments, such as hospitals, academic institutes, and diagnostic centres.
Preview Liquid Biopsy Market Segmentation By Marker Type - Circulating Tumour Cells (ctcs), Ctna Circulating Tumour Nucleic Acids (ctna), and Exosomes; By Sample Type - Blood, Urine, and Others (Plasma, Saliva, Cerebrospinal Fluid); By Disease Indication - Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer, Colorectal, Leukemia and Others; By End User - Hospitals, Cancer Institutes, Academic Institutes and Diagnostic Centres: https://www.futuremarketinsights.com/reports/...psy-market
Some of the key players in the global liquid biopsy market include Genomic Health, Inc., Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation. A majority of key companies are concentrating on mergers, acquisitions, and partnerships; while most of them are prioritising innovative diagnostics and technological upgrades for better penetration in developing regional markets.
Long term outlook: The global liquid biopsy market is projected to expand at a CAGR of 21.7% by 2026 end, reaching a value of US$ 2.89 Bn.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-1396
More from FMI’s Healthcare, Pharmaceuticals & Medical Devices:
- Cancer Diagnostics Market Segmentation By Test Type – Tumour Biomarkers Tests, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridisation; By End User – Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, Others; By Indication – Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others: https://www.futuremarketinsights.com/reports/...ics-market
- Liquid Biopsy Market Segmentation by Biomarker Type - CTCs (Circulating tumour Cells), ctNA (Circulating tumour Nucleic Acids), Exosomes; Sample - Blood, Urine, Others (Plasma, Saliva, CSF); Disease Indication - Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Others; End User - Hospitals, Cancer Institutes, Academic Institutes, Diagnostic Centers: https://www.futuremarketinsights.com/reports/...ket-112017
- Biopsy Device Market Segmentation By Product Type - Guidance System (Stereotactic X-Ray Guided Biopsy, Ultrasound Guided Biopsy, MRI Guided Biopsy), Needles (Core Needles, Fine Aspiration Needles), Guns and Others (Brushes, Curettes and Punches Etc.); By Application - Medical Diagnosis and Scientific Research; By End Use - Hospital, Specialised Oncology Centres, Diagnostic Centres and Research Institutes: https://www.futuremarketinsights.com/reports/...ice-market
About Us
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Browse More: Healthcare, Pharmaceuticals & Medical Devices
Contact Us
Mr. Sudip Saha Future Market Insights 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F : +1-845-579-5705 T (UK): + 44 (0) 20 7692 8790 Sales: sales@futuremarketinsights.com Press Office : Press@futuremrketinsights.com FMI Blog: http://www.fmiblog.com/ Website : www.futuremarketinsights.com
